Market closed
Aerovate Therapeutics/AVTE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aerovate Therapeutics
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
Ticker
AVTE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
51
Website
AVTE Metrics
BasicAdvanced
$61M
Market cap
-
P/E ratio
-$3.13
EPS
1.02
Beta
-
Dividend rate
Price and volume
Market cap
$61M
Beta
1.02
52-week high
$32.42
52-week low
$1.25
Average daily volume
197K
Financial strength
Current ratio
6.508
Quick ratio
6.122
Long term debt to equity
0.218
Total debt to equity
0.721
Management effectiveness
Return on assets (TTM)
-44.03%
Return on equity (TTM)
-74.42%
Valuation
Price to book
0.64
Price to tangible book (TTM)
0.64
Price to free cash flow (TTM)
-0.792
Growth
Earnings per share change (TTM)
20.62%
3-year earnings per share growth (CAGR)
-62.75%
What the Analysts think about AVTE
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Aerovate Therapeutics stock.
AVTE Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AVTE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aerovate Therapeutics stock?
Aerovate Therapeutics (AVTE) has a market cap of $61M as of October 26, 2024.
What is the P/E ratio for Aerovate Therapeutics stock?
The price to earnings (P/E) ratio for Aerovate Therapeutics (AVTE) stock is 0 as of October 26, 2024.
Does Aerovate Therapeutics stock pay dividends?
No, Aerovate Therapeutics (AVTE) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Aerovate Therapeutics dividend payment date?
Aerovate Therapeutics (AVTE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aerovate Therapeutics?
Aerovate Therapeutics (AVTE) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.